Progress of molecular targeted therapies for prostate cancers

Abstract

Prostate cancer remains the most commonly diagnosed malignancy and the second leading cause of cancer-related deaths in men in the United States. The current standard of care consists of prostatectomy and radiation therapy, which may often be supplemented with hormonal therapies. Recurrence is common, and many develop metastatic prostate cancer for which chemotherapy is only moderately effective. It is clear that novel therapies are needed for the treatment of the malignant forms of prostate cancer that recur after initial therapies, such as hormone refractory (HRPC) or castration resistant prostate cancer (CRPC). With advances in understanding of the molecular mechanisms of cancer, we have witnessed unprecedented progress in developing new forms of targeted therapy. Several targeted therapeutic agents have been developed and clinically used for the treatment of solid tumors such as breast cancer, non-small cell lung cancer, and renal cancer. Some of these reagents modulate growth factors and/or their receptors, which are abundant in cancer cells. Other reagents target the downstream signal transduction, survival pathways, and angiogenesis pathways that are abnormally activated in transformed cells or metastatic tumors. We will review current developments in this field, focusing specifically on treatments that can be applied to prostate cancers. Finally we will describe aspects of the future direction of the field with respect to discovering biomarkers to aid in identifying responsive prostate cancer patients.

Ovarian cancer transformation from adenocarcinoma to undifferentiated small cell carcinoma: A case report

“…If a signal pathway is terminated or weakened by medicine or other interventions, such as pre-operative chemotherapy, radiation, its impaired function would be replaced by other signaling pathways (8). This is a likely cause of the change in malignant pathological type following treatment.…”

Identification of Androgen Receptor Splice Variant Transcripts in Breast Cancer Cell Lines and Human Tissues

“…Indeed, AR is considered the key oncogenic driver at all stages of prostate cancer. Accordingly, androgen deprivation therapy (ADT), achieved via blockage of androgen production through castration and/or antagonism of AR activity by antiandrogens, forms the cornerstone of endocrine therapy for this disease [4]. Despite an initial response to ADT, men with prostate cancer invariably progress to an incurable state called castration-resistant prostate cancer (CRPC), thought to occur via therapy-driven adaptive mechanisms that sustain or resurrect an active AR signaling axis in prostate cancer cells [5].…”

Targeting the Metastasis Suppressor, NDRG1, Using Novel Iron Chelators: Regulation of Stress Fiber-Mediated Tumor Cell Migration via Modulation of the ROCK1/pMLC2 Signaling Pathway

“…Thus, new approaches to prostate and colorectal cancer treatment have focused on therapeutically targeting crucial molecules involved in disease progression (Fu et al, 2012;Tsujii, 2012). One newly identified molecular target, namely the metastasis suppressor, N-myc downstream regulated gene-1 (NDRG1), has been reported to inhibit prostate and colorectal cancer progression (Guan et al, 2000;Liu et al, 2011).…”